Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.

Antibiotic administration disrupts the intestinal microbiota, increasing susceptibility to pathogens such as Clostridium difficile. Metronidazole or oral vancomycin can cure C. difficile infection, and administration of these agents to prevent C. difficile infection in high-risk patients, although not sanctioned by Infectious Disease Society of America guidelines, has been considered. The relative impacts of metronidazole and vancomycin on the intestinal microbiota and colonization resistance are unknown. We investigated the effect of brief treatment with metronidazole and/or oral vancomycin on susceptibility to C. difficile, vancomycin-resistant Enterococcus, carbapenem-resistant Klebsiella pneumoniae, and Escherichia coli infection in mice. Although metronidazole resulted in transient loss of colonization resistance, oral vancomycin markedly disrupted the microbiota, leading to prolonged loss of colonization resistance to C. difficile infection and dense colonization by vancomycin-resistant Enterococcus, K. pneumoniae, and E. coli. Our results demonstrate that vancomycin, and to a lesser extent metronidazole, are associated with marked intestinal microbiota destruction and greater risk of colonization by nosocomial pathogens.

[1]  C. Bassis,et al.  Alteration of the Murine Gastrointestinal Microbiota by Tigecycline Leads to Increased Susceptibility to Clostridium difficile Infection , 2014, Antimicrobial Agents and Chemotherapy.

[2]  C. Donskey,et al.  Appropriateness of empiric therapy in patients with suspected Clostridium difficile infection , 2013, Current medical research and opinion.

[3]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[4]  Melinda B Davis,et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Jeffrey D Goldsmith,et al.  A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.

[6]  R. Knight,et al.  UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.

[7]  R. Owens,et al.  Clostridium difficile–Associated Disease: An Emerging Threat to Patient Safety: Insights from the Society of Infectious Diseases Pharmacists , 2006, Pharmacotherapy.

[8]  Martin Hartmann,et al.  Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.

[9]  T. Peto,et al.  Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile , 2013, The Journal of infectious diseases.

[10]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[11]  D. Musher,et al.  Treatment of Clostridium difficile-associated disease: old therapies and new strategies. , 2005, The Lancet. Infectious diseases.

[12]  L. Valiquette,et al.  Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses , 2011 .

[13]  Chris Sander,et al.  Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile , 2014, Nature.

[14]  R. Guerrant,et al.  Vancomycin Treatment's Association with Delayed Intestinal Tissue Injury, Clostridial Overgrowth, and Recurrence of Clostridium difficile Infection in Mice , 2012, Antimicrobial Agents and Chemotherapy.

[15]  T. Riley,et al.  Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[16]  L. Brandt,et al.  The Evolution of Urban C. difficile Infection (CDI): CDI in 2009–2011 Is Less Severe and has Better Outcomes Than CDI in 2006–2008 , 2014, The American Journal of Gastroenterology.

[17]  J. Bartlett,et al.  Historical perspectives on studies of Clostridium difficile and C. difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Viale,et al.  Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced Colitis , 2011, Infection and Immunity.

[19]  N. Socci,et al.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.

[20]  K. Garey,et al.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.

[21]  M. Pirmohamed,et al.  Emergence and global spread of epidemic healthcare-associated Clostridium difficile , 2012, Nature Genetics.

[22]  A. Viale,et al.  Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice , 2012, The Journal of experimental medicine.

[23]  T. Louie,et al.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[25]  C. Donskey,et al.  Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole , 2013, PloS one.

[26]  N. Khardori Clostridium difficile infection in Europe: a hospital-based survey , 2011 .

[27]  James A. Foster,et al.  Phylogenetics Clearcut : a fast implementation of relaxed neighbor joining , 2006 .

[28]  S. Rodríguez,et al.  Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  T. Wilt,et al.  Comparative Effectiveness of Clostridium difficile Treatments , 2011, Annals of Internal Medicine.

[30]  Eoin L. Brodie,et al.  Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB , 2006, Applied and Environmental Microbiology.

[31]  Marti J. Anderson,et al.  A new method for non-parametric multivariate analysis of variance in ecology , 2001 .